Figure Legends
Figure 1A. Whole patient cohort separated into treatment
groups, dupilumab (n=631), other systemics (n=107), and limited/no
treatment (n=495), grouping symptom severity in each treatment group by
scores of 0-1 (asymptomatic or mild symptoms) and 2-5 (moderately
symptomatic to fatal). *P<0.05. **P<0.01.1B. Whole patient cohort separated into treatment groups,
dupilumab (n=631), other systemics (n=107), and limited/no treatment
(n=495), grouping presence of symptoms in each treatment group by a
score of 0 (asymptomatic) or 1-5 (symptomatic). *P<0.05.
**P<0.01.
Figure 2A. Cohort of patients with known infection or high risk
COVID-19 exposures, separated into treatment groups, dupilumab (n=164),
other systemics (n=26), and limited/no treatment (n=116), grouping
symptom severity in each treatment group by scores of 0-1 (asymptomatic
or mild symptoms) and 2-5 (moderately symptomatic to fatal).
*P<0.05. **P<0.01. 2B. Cohort of patients
with known infection or high risk COVID-19 exposures, separated into
treatment groups, dupilumab (n=164), other systemics (n=26), and
limited/no treatment (n=116), grouping presence of symptoms in each
treatment group by a score of 0 (asymptomatic) or 1-5 (symptomatic).
*P<0.05. **P<0.01.